Roche, GA-101 could get first approval as early as December 2013

News published on July Wednesday 3, 2013
Share on

Roche is reporting that the FDA has accepted to grant GA-101 Breathrough Therapy Designation and its BLA a priority review based on the stage 1 data of the pivotal CLL11 trial, thus installing an action date for December 20, 2013. This is once again recognition of the highly valuable and meaningful results presented at the ASCO meeting in late May.


Full report available to subscribers
Please contact marketing@bryangarnier.fr

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities